You are viewing articles tagged with "During 03/2020".
Renin-Angiotensin System Blockers and the COVID-19 Pandemic
At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
A.H. Jan Danser, Murray Epstein, Daniel Batlle
Read More 26/03/2020
The organizing committee of the 2020 ESH-ISH Joint Meeting in Glasgow, would like to inform you that in view of the global unprecedented situation related to COVID-19, the ESH-ISH Joint Meeting, has been rescheduled to April 11-14, 2021.
Read More 23/03/2020
The International Society of Hypertension (ISH) is aware of concern raised by speculation, which was amplified by the media and which suggested that hypertension (raised blood pressure) increases susceptibility to infection with COVID-19. Further speculation reportedly suggested that two commonly used classes of blood pressure lowering agents (ACE-Inhibitors and Angiotensin Receptor Blockers (ARBs)) may worsen the outcome for those who are infected with COVID-19 (1).
The ISH completely endorses the content of two recent statements made by the Council on Hypertension of the European Society of Cardiology and the European Society of Hypertension (2,3) both of which made clear that there is no good evidence to change the use of ACE-inhibitors or ARBs for the management of raised blood pressure in the context of avoiding or treating COVID-19 infection.
Read More 16/03/2020